HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fetal antisense oligonucleotide therapy for congenital deafness and vestibular dysfunction.

Abstract
Disabling hearing loss impacts ∼466 million individuals worldwide with 34 million children affected. Gene and pharmacotherapeutic strategies to rescue auditory function in mouse models of human deafness are most effective when administered before hearing onset, after which therapeutic efficacy is significantly diminished or lost. We hypothesize that preemptive correction of a mutation in the fetal inner ear prior to maturation of the sensory epithelium will optimally restore sensory function. We previously demonstrated that transuterine microinjection of a splice-switching antisense oligonucleotide (ASO) into the amniotic cavity immediately surrounding the embryo on embryonic day 13-13.5 (E13-13.5) corrected pre-mRNA splicing in the juvenile Usher syndrome type 1c (Ush1c) mouse mutant. Here, we show that this strategy only marginally rescues hearing and partially rescues vestibular function. To improve therapeutic outcomes, we microinjected ASO directly into the E12.5 inner ear. A single intra-otic dose of ASO corrects harmonin RNA splicing, restores harmonin protein expression in sensory hair cell bundles, prevents hair cell loss, improves hearing sensitivity, and ameliorates vestibular dysfunction. Improvements in auditory and vestibular function were sustained well into adulthood. Our results demonstrate that an ASO pharmacotherapeutic administered to a developing organ system in utero preemptively corrects pre-mRNA splicing to abrogate the disease phenotype.
AuthorsLingyan Wang, J Beth Kempton, Han Jiang, Francine M Jodelka, Alev M Brigande, Rachel A Dumont, Frank Rigo, Jennifer J Lentz, Michelle L Hastings, John V Brigande
JournalNucleic acids research (Nucleic Acids Res) Vol. 48 Issue 9 Pg. 5065-5080 (05 21 2020) ISSN: 1362-4962 [Electronic] England
PMID32249312 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.
Chemical References
  • Cell Cycle Proteins
  • Cytoskeletal Proteins
  • Oligonucleotides, Antisense
  • Ush1c protein, mouse
Topics
  • Amnion
  • Animals
  • Auditory Threshold (drug effects)
  • Cell Cycle Proteins (genetics, metabolism)
  • Cytoskeletal Proteins (genetics, metabolism)
  • Deafness (congenital, drug therapy, genetics, physiopathology)
  • Ear, Inner (drug effects, metabolism)
  • Fetus
  • Hair Cells, Auditory (drug effects, metabolism, ultrastructure)
  • Mice
  • Microinjections
  • Mutation
  • Oligonucleotides, Antisense (administration & dosage, therapeutic use)
  • RNA Splicing (drug effects)
  • Vestibule, Labyrinth (drug effects, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: